Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.25 AUD | +2.42% | +0.66% | -4.69% |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Sales 2024 * | 89.47M 58.31M | Sales 2025 * | 98.61M 64.26M | Capitalization | 746M 486M |
---|---|---|---|---|---|
Net income 2024 * | 34M 22.16M | Net income 2025 * | 37M 24.11M | EV / Sales 2024 * | 6.25 x |
Net cash position 2024 * | 187M 122M | Net cash position 2025 * | 219M 143M | EV / Sales 2025 * | 5.34 x |
P/E ratio 2024 * |
21.7
x | P/E ratio 2025 * |
20.1
x | Employees | - |
Yield 2024 * |
0.45% | Yield 2025 * |
0.5% | Free-Float | 79.56% |
Latest transcript on Clinuvel Pharmaceuticals Limited
1 day | +2.48% | ||
1 week | +0.73% | ||
Current month | +6.27% | ||
1 month | +11.79% | ||
3 months | -1.36% | ||
6 months | +0.13% | ||
Current year | -4.62% |
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 15.25 | +2.42% | 83 059 |
24-04-23 | 14.89 | +4.49% | 75,814 |
24-04-22 | 14.25 | -0.90% | 122,966 |
24-04-19 | 14.38 | -5.95% | 254,065 |
24-04-18 | 15.29 | +0.92% | 62,525 |
Delayed Quote Australian S.E., April 23, 2024 at 11:51 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.62% | 460M | |
-2.69% | 85.68B | |
+4.08% | 41.4B | |
-25.35% | 28.22B | |
+54.31% | 24.64B | |
-4.52% | 16.98B | |
-42.09% | 13.29B | |
-17.77% | 11.66B | |
-12.10% | 11.65B | |
+0.75% | 8.18B |
- Stock Market
- Equities
- CUV Stock